scholarly journals Japanese Encephalitis: a life threatening disease

2018 ◽  
Vol 6 (1) ◽  
Author(s):  
Pushkar Singh Rawat ◽  
Kajal Patel ◽  
Sudhir Mehrotra

Japanese encephalitis (JE) is neurological infection which is caused by Japanese encephalitis virus (JEV), a flavivirus, and is closely related to St. Louis encephalitis and West Nile encephalitis. It is predominant in rural areas of Asia, which spread through bites of culicine mosquitoes, most often Culex tritaeniorhynchus. JE has broad range of manifestations. It can range from subtle changes in behavior to serious problems, including blindness, ataxia, weakness, and movement disorders.Japanese encephalitis virus is endemic in 24 countries in Southeast Asia and Western Pacific regions with more than 3 billion people at risk of infection. JE is the main cause of viral encephalitis in people in many countries of Asia amounting almost 68,000 clinical cases per year. Children are at greatest risk, with adults in endemic areas having protective immunity as a consequence of childhood infection. This disease is of particular importance in Gorakhpur, eastern belt of UP, the state with the largest population in India, where a large number of children have been dying in the past several years with alarming frequency since 1978.

2007 ◽  
Vol 30 (2) ◽  
pp. 205-214 ◽  
Author(s):  
Cheng-Wen Lin ◽  
Kuang-Ting Liu ◽  
Hong-Da Huang ◽  
Wei-June Chen

1991 ◽  
Vol 35 (10) ◽  
pp. 863-870 ◽  
Author(s):  
Ashok Kumar Srivastava ◽  
Kouichi Morita ◽  
Sachiko Matsuo ◽  
Mariko Tanaka ◽  
Akira Igarashi

2008 ◽  
Vol 83 (6) ◽  
pp. 2436-2445 ◽  
Author(s):  
Mario Lobigs ◽  
Maximilian Larena ◽  
Mohammed Alsharifi ◽  
Eva Lee ◽  
Megan Pavy

ABSTRACT The Japanese encephalitis virus (JEV) serocomplex, which also includes Murray Valley encephalitis virus (MVEV), is a group of antigenically closely related, mosquito-borne flaviviruses that are responsible for severe encephalitic disease in humans. While vaccines against the prominent members of this serocomplex are available or under development, it is unlikely that they will be produced specifically against those viruses which cause less-frequent disease, such as MVEV. Here we have evaluated the cross-protective values of an inactivated JEV vaccine (JE-VAX) and a live chimeric JEV vaccine (ChimeriVax-JE) against MVEV in two mouse models of flaviviral encephalitis. We show that (i) a three-dose vaccination schedule with JE-VAX provides cross-protective immunity, albeit only partial in the more severe challenge model; (ii) a single dose of ChimeriVax-JE gives complete protection in both challenge models; (iii) the cross-protective immunity elicited with ChimeriVax-JE is durable (≥5 months) and broad (also giving protection against West Nile virus); (iv) humoral and cellular immunities elicited with ChimeriVax-JE contribute to protection against lethal challenge with MVEV; (v) ChimeriVax-JE remains fully attenuated in immunodeficient mice lacking type I and type II interferon responses; and (vi) immunization with JE-VAX, but not ChimeriVax-JE, can prime heterologous infection enhancement in recipients of vaccination on a low-dose schedule, designed to mimic vaccine failure or waning of vaccine-induced immunity. Our results suggest that the live chimeric JEV vaccine will protect against other viruses belonging to the JEV serocomplex, consistent with the observation of cross-protection following live virus infections.


2016 ◽  
Vol 52 (02) ◽  
pp. 100-108
Author(s):  
Milind M. Gore

ABSTRACTJapanese encephalitis virus (JEV) is a major seasonal health problem in many rural areas in India and other parts of Asia. Transmission of virus is through mosquito vectors biting followed by peripheral multiplication site and exposed to host immune response before it succeeds in invasion of CNS. Thus protection from viral infection is a complex interplay of fight for superiority by virus and the host.Cell mediated immune response using transferred to non-immune 14 day mice and lethally challenged to study the protection. Results indicated that dominant immune response of T helper (Th) 2 type. Th and neutralizing antibody inducing epitopes on JEV were identified by combination of immunological and Bioinformatics platforms. Chimeric peptides incorporating both Th and B cell epitopes could protect mice. These epitopes were further incorporated in polytope DNA construct with four chimeric peptides and induce protective immunity in mice. In addition, overcome the anergy development by traditional DNA vaccine plasmid than of CMV promoter using antigen specific cell promoter rather was also studied.NIV carried out extensive studies on JE inactivated vaccines over the years. Studies were carried out mainly using CEC and Vero cells. Isolated of JEV from Kolar (821564) was extensively studied and thermostable mutant (821564 –XY) was selected and characterized genetically as well as antigenically. A commercial successfully produced purified, inactivated vaccine JENVAC is licensed is being successfully. Future challenges in terms of single dose vaccine with long lasting immunity, pig immunization vaccine as well newer related flavivirus are also important.


2012 ◽  
Vol 9 (1) ◽  
pp. 135 ◽  
Author(s):  
Yize Li ◽  
Dorian Counor ◽  
Peng Lu ◽  
Veasna Duong ◽  
Yongxin Yu ◽  
...  

2004 ◽  
Vol 48 (8) ◽  
pp. 585-590 ◽  
Author(s):  
Yushui Wu ◽  
Fuquan Zhang ◽  
Wenyu Ma ◽  
Jianhua Song ◽  
Qingsheng Huang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document